Bioperfectus Launching HPV Series Real Time PCR Kit to the Global Market

Company news



Cervical canceris a life-threating disease in the women’s cervix, which is the fourth killer among cancers for females.


The infection of high-riskHPVhas a strong association with incidence of cervical cancer.There are more than 100 types of HPV. Each type has specific preferred infected area. These HPV can be classified into two groups according to the potential risks to develop cancer, high-risk HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59, 66 and 68) and low-risk HPV (6, 11, 81).


With the dedication to building a healthier life for human being, today weBioperfectusare glad to launch our HPV series Real Time PCR Kits (Human Papillomavirus Real Time PCR Kit& Human Papillomavirus Genotyping Real Time PCR Kit) to the global market.


Bioperfectus Human Papillomavirus Real Time PCR Kitis a qualitative PCR assay intended to detect 18 high-risk genotypes of the human papillomavirus (HPV), including HPV-16, HPV-18 and other 16 common oncogenic types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, 53, 82 and 26). It has high specificity and sensitivity, can be used for primary cervical cancer screening. Specific genotypes identified can assist doctors to further decide triage and treatment and  reduce morbidity and prevalence of cervical cancer. 


Screening high-risk HPV can avoid unnecessary colposcopy procedures and improve the clinical management. When certain type of HPV is identified more than once during 6 months, the patient can be considered as constant infection and further triage should be taken. It enables women to access to diagnosis at the early stage of HPV infection and to get treatment before development of precancerous lesions and cervical cancer.  Bioperfectus Human Papillomavirus Genotyping Real Time PCR Kit accurately detecting and reporting 21 types of HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 26, 73, 82, 6, 11, 81).


There is power in early diagnosis and prevention.


Inquiry regarding the product, please send email &


Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.


Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.


Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).